Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]
M Körbling(The University of Texas Health Science Center at Houston), AB Deisseroth(The University of Texas MD Anderson Cancer Center), Koen van Besien(University Hospitals of Cleveland), Heike Engel(The University of Texas MD Anderson Cancer Center), Donna Przepiorka(The University of Texas MD Anderson Cancer Center), Börje S. Andersson(The University of Texas MD Anderson Cancer Center), YO Huh(The University of Texas MD Anderson Cancer Center), H.-D. Kleine(The University of Texas MD Anderson Cancer Center), Sergio Giralt(Memorial Sloan Kettering Cancer Center), David Seong(Stanford Medicine)
Cited by 539
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k